+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Epigenetics Drugs and Diagnostic Technologies Market (2023-2028) by Product, Technique, Methods, Application, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis

  • PDF Icon


  • 139 Pages
  • July 2023
  • Region: Global
  • Infogence Global Research
  • ID: 5669276
UP TO OFF until Dec 31st 2023

Quick Summary:

In the rapidly evolving healthcare landscape, staying at the forefront of innovation and technological advancements is critical. For stakeholders seeking to navigate this complex arena, the Global Epigenetics Drugs and Diagnostic Technologies Market Report is a comprehensive guide.

Epigenetic drugs and diagnostic technologies have emerged as breakthrough advancements with huge potential to revolutionize healthcare. They offer fresh insights into gene expression and the influence of environmental factors on genetics, fuelling the discovery of improved, personalized therapies. Rising prevalence of chronic and genetic diseases drive the urgency for more precise, focused medicines and diagnostics, making this report key for business leaders seeking to identify new growth opportunities.

Investments and supportive initiatives by governments globally, coupled with increased manufacturing investments by pharmaceutical and biotechnical companies form key market drivers. Further, ongoing research, unveiling new epigenetic targets, fuels innovation and diversity, expanding the market's potential for those willing to invest. Finally, new infectious diseases present a pressing demand for innovative epigenetic solutions, holding lucrative market prospects.

While the promise is great, uncovering the full potential of epigenetics faces challenges, such as the lack of specialists and limited understanding of epigenetic mechanisms. Unlocking these hurdles through enhancing research efforts and bridging the skills gap is crucial to fully exploit these cutting-edge technologies. This report equips you with the essential information to navigate these challenges and seize significant growth opportunities in the global epigenetics market.

Market is advancing with epigenetic-targeted therapies and non-invasive epigenetic biomarker testing

The Global Epigenetics Drugs and Diagnostic Technologies Market is estimated to be USD 12.08 Bn in 2023 and is expected to reach USD 30.19 Bn by 2028, growing at a CAGR of 20.1%.

Epigenetic medicines modify gene expression without changing DNA sequences by targeting chemical alterations of genes. Epigenetic diagnostic methods examine epigenetic markers to diagnose and assess disease. These advancements can potentially revolutionize healthcare practices by improving personalized therapy and understanding how environmental factors influence genetic function.

The enormous rise in the prevalence of chronic and genetic diseases worldwide has increased the need for new treatments, such as epigenetic medicines and diagnostic tools. As these diseases become increasingly common, there is an urgent need to develop focused medicines and precise diagnostics to better understand and treat these complicated diseases. Epigenetics can reveal new insights into disease causes and give patients with personalized therapy alternatives.

Government initiatives and investments in drug discovery and development have helped to boost the epigenetics industry. Governments recognize the promise of epigenetics to transform healthcare and support it through financing, grants, and regulatory incentives. This funding promotes epigenetics research and development, supporting the development of innovative medications and diagnostics with improved efficacy and safety profiles, hence driving market growth.

Rising pharmaceutical and biopharmaceutical manufacturing investments have fueled the epigenetics market even more. As the demand for precision medicine and personalized therapeutics grows, pharmaceutical companies are investing in innovative epigenetic technologies and platforms. The influx of resources leads to the development of more advanced and accessible epigenetic medications and diagnostic tools, increasing the market's growth potential.

Ongoing epigenetics research and development initiatives create enormous opportunities for businesses. Scientists and biotech businesses always seek new epigenetic targets and mechanisms to develop more effective medications and diagnostic tools. This fast-paced environment encourages innovation, advancing the market with potential breakthroughs and increased uses in various disease areas.

The rise of new infectious diseases worldwide urgently demands fresh epigenetic remedies. Understanding epigenetic mechanisms, which play a critical role in regulating infectious pathogens, can lead to the creation of targeted medicines and quick diagnostic tools. As new infectious diseases emerge, there will be greater demand for epigenetics-based therapies, creating attractive market opportunities.

However, the market restriction of limited applications in epigenetics relates to the current depth and understanding of epigenetic mechanisms, which may limit its full potential in addressing various diseases and situations. More research and development are required to uncover larger applications and fully leverage its benefits in healthcare.

Scarcity of competent people for epigenetics research and development activities refers to a lack of specialized experts with the requisite knowledge and ability to drive developments in this complicated sector. It is critical to address this shortfall in order to accelerate progress and realize the full promise of epigenetics in healthcare.

Market Segmentations

The Global Epigenetics Drugs and Diagnostic Technologies Market is segmented based on Product, Technique, Methods, Application, End User, and Geography.
  • By Product, the Global Epigenetics Drugs and Diagnostic Technologies Market is classified into Enzymes, Instruments & Accessories, Reagents & Kits, Services, and Software.
Reagents & Kits hold a larger market share. These critical components are widely used in a variety of research and diagnostic applications, driving their popularity and demand. Reagents and Kits are essential in conducting experiments and analysis.
  • By Technique, the Global Epigenetics Drugs and Diagnostic Technologies Market is classified into Mass Spectrometry, NGS, PCR & qPCR, and Sonication.
Next-Generation Sequencing (NGS) holds a significant market share. NGS provides high-throughput and comprehensive epigenetic modification analysis, making it a popular choice among academics and physicians. Its ability to give detailed data has led to widespread adoption in a variety of applications, leading to its market dominance.
  • By Methods, the Global Epigenetics Drugs and Diagnostic Technologies Market is classified into DNA Methylation and Histone Modifications.
DNA Methylation holds a larger market share. Due to its importance in gene regulation and disease development, DNA methylation is widely explored. Because of its established significance, it has spawned a plethora of commercial products and applications.
  • By Application, the Global Epigenetics Drugs and Diagnostic Technologies Market is classified into Cardiovascular Diseases, Developmental Biology, Immunology, Metabolic Diseases, and Oncology.
Oncology holds a significant market share. Understanding epigenetic alterations in cancer has led to the development of targeted medicines and diagnostic tools, driving substantial research and investment in this area and leading to its dominant market position.
  • By End-User, the Global Epigenetics Drugs and Diagnostic Technologies Market is classified into Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
Pharmaceutical & Biotechnology Companies holds a larger market share. These companies extensively spend in epigenetic medication and diagnostic research, development, and commercialization, resulting in tremendous growth.
  • By Geography, the Global Epigenetics Drugs and Diagnostic Technologies Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
The Americas hold a significant market share. The region's excellent healthcare infrastructure, research funding, and advanced biotechnology sectors have led to the region's market dominance in epigenetics.

Recent Developments

Cardio Diagnostics Holdings, Inc’s Actionable Clinical IntelligenceTM (ACI) Platform Offers New Epigenetic and Genetic Insights to Inform Coronary Heart Disease Management - May 2023

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Active Motif, Inc., Diagenode, GenomeScan, PerkinElmer, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Epigenetics Drugs and Diagnostic Technologies Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Epigenetics Drugs and Diagnostic Technologies Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, The analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Epigenetics Drugs and Diagnostic Technologies Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

This product will be delivered within 2 business days.
Frequently Asked Questions about the Global Epigenetics Drugs and Diagnostic Technologies Market

What is the estimated value of the Global Epigenetics Drugs and Diagnostic Technologies Market?

The Global Epigenetics Drugs and Diagnostic Technologies Market was estimated to be valued at $12.08 Billion in 2023.

What is the growth rate of the Global Epigenetics Drugs and Diagnostic Technologies Market?

The growth rate of the Global Epigenetics Drugs and Diagnostic Technologies Market is 20.1%, with an estimated value of $30.19 Billion by 2028.

What is the forecasted size of the Global Epigenetics Drugs and Diagnostic Technologies Market?

The Global Epigenetics Drugs and Diagnostic Technologies Market is estimated to be worth $30.19 Billion by 2028.

Who are the key companies in the Global Epigenetics Drugs and Diagnostic Technologies Market?

Key companies in the Global Epigenetics Drugs and Diagnostic Technologies Market include Abcam, PLC, Active Motif, Inc., Bio, Rad Laboratories, Creative Biogene, Diagenode, EpiCypher, EpiGentek Group, Inc., Everon Life Sciences and F Hoffmann.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Analyst Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Significant Growth in Prevalence of Chronic and Genetic Disorders Worldwide
4.2.2 Favorable Governmental Initiatives and Investments in Drug Discovery and Development
4.2.3 Rising Investments in Pharmaceuticals and Biopharmaceuticals Manufacturing
4.3 Restraints
4.3.1 Limited Applications of Epigenetics
4.4 Opportunities
4.4.1 Ongoing Research and Development Activities for Advancement of Epigenetics
4.4.2 Emergence of Novel Infectious Disorders Worldwide
4.5 Challenges
4.5.1 Scarcity of Skilled Professionals for Research and Development Activities
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Epigenetics Drugs and Diagnostic Technologies Market, By Product
6.1 Introduction
6.2 Enzymes
6.3 Instruments & Accessories
6.4 Reagents & Kits
6.5 Service
6.6 Software
7 Global Epigenetics Drugs and Diagnostic Technologies Market, By Technique
7.1 Introduction
7.2 Mass Spectrometry
7.3 NGS
7.4 PCR & qPCR
7.5 Sonication
8 Global Epigenetics Drugs and Diagnostic Technologies Market, By Methods
8.1 Introduction
8.2 DNA Methylation
8.3 Histone Modifications
9 Global Epigenetics Drugs and Diagnostic Technologies Market, By Application
9.1 Introduction
9.2 Cardiovascular Diseases
9.3 Developmental Biology
9.4 Immunology
9.5 Metabolic Diseases
9.6 Oncology
10 Global Epigenetics Drugs and Diagnostic Technologies Market, By End User
10.1 Introduction
10.2 Academic & Research Institutes
10.3 Contract Research Organizations
10.4 Pharmaceutical & Biotechnology Companies
11 America’s Epigenetics Drugs and Diagnostic Technologies Market
11.1 Introduction
11.2 Argentina
11.3 Brazil
11.4 Canada
11.5 Chile
11.6 Colombia
11.7 Mexico
11.8 Peru
11.9 United States
11.10 Rest of Americas
12 Europe's Epigenetics Drugs and Diagnostic Technologies Market
12.1 Introduction
12.2 Austria
12.3 Belgium
12.4 Denmark
12.5 Finland
12.6 France
12.7 Germany
12.8 Ireland
12.9 Italy
12.10 Luxembourg
12.11 Netherlands
12.12 Norway
12.13 Poland
12.14 Russia
12.15 Spain
12.16 Sweden
12.17 Switzerland
12.18 United Kingdom
12.19 Rest of Europe
13 Middle East and Africa's Epigenetics Drugs and Diagnostic Technologies Market
13.1 Introduction
13.2 Egypt
13.3 Israel
13.4 Qatar
13.5 Nigeria
13.6 Saudi Arabia
13.7 South Africa
13.8 United Arab Emirates
13.9 Rest of MEA
14 APAC's Epigenetics Drugs and Diagnostic Technologies Market
14.1 Introduction
14.2 Australia
14.3 Bangladesh
14.4 China
14.5 India
14.6 Indonesia
14.7 Japan
14.8 Malaysia
14.9 Philippines
14.10 Singapore
14.11 South Korea
14.12 Sri Lanka
14.13 Thailand
14.14 Taiwan
14.15 Rest of Asia-Pacific
15 Competitive Landscape
15.1 Analyst Competitive Quadrant
15.2 Market Share Analysis
16 Company Profiles
16.1 Abcam, PLC
16.1.1 Company Overview
16.1.2 Company Snapshot
16.1.3 Product Overview
16.1.4 Business Overview
16.1.5 SWOT Analysis
16.1.6 Recent Developments
16.2 Active Motif, Inc.
16.2.1 Company Overview
16.2.2 Company Snapshot
16.2.3 Product Overview
16.2.4 Business Overview
16.2.5 SWOT Analysis
16.2.6 Recent Developments
16.3 Bio-Rad Laboratories
16.3.1 Company Overview
16.3.2 Company Snapshot
16.3.3 Product Overview
16.3.4 Business Overview
16.3.5 SWOT Analysis
16.3.6 Recent Developments
16.4 Creative Biogene
16.4.1 Company Overview
16.4.2 Company Snapshot
16.4.3 Product Overview
16.4.4 Business Overview
16.4.5 SWOT Analysis
16.4.6 Recent Developments
16.5 Diagenode
16.5.1 Company Overview
16.5.2 Company Snapshot
16.5.3 Product Overview
16.5.4 Business Overview
16.5.5 SWOT Analysis
16.5.6 Recent Developments
16.6 EpiCypher
16.6.1 Company Overview
16.6.2 Company Snapshot
16.6.3 Product Overview
16.6.4 Business Overview
16.6.5 SWOT Analysis
16.6.6 Recent Developments
16.7 EpiGentek Group, Inc.
16.7.1 Company Overview
16.7.2 Company Snapshot
16.7.3 Product Overview
16.7.4 Business Overview
16.7.5 SWOT Analysis
16.7.6 Recent Developments
16.8 Everon Life Sciences
16.8.1 Company Overview
16.8.2 Company Snapshot
16.8.3 Product Overview
16.8.4 Business Overview
16.8.5 SWOT Analysis
16.8.6 Recent Developments
16.9 F Hoffmann-La Roche, Ltd.
16.9.1 Company Overview
16.9.2 Company Snapshot
16.9.3 Product Overview
16.9.4 Business Overview
16.9.5 SWOT Analysis
16.9.6 Recent Developments
16.10 Fios Genomics
16.10.1 Company Overview
16.10.2 Company Snapshot
16.10.3 Product Overview
16.10.4 Business Overview
16.10.5 SWOT Analysis
16.10.6 Recent Developments
16.11 GenomeScan
16.11.1 Company Overview
16.11.2 Company Snapshot
16.11.3 Product Overview
16.11.4 Business Overview
16.11.5 SWOT Analysis
16.11.6 Recent Developments
16.12 Illumina, Inc.
16.12.1 Company Overview
16.12.2 Company Snapshot
16.12.3 Product Overview
16.12.4 Business Overview
16.12.5 SWOT Analysis
16.12.6 Recent Developments
16.13 Merck KGaA
16.13.1 Company Overview
16.13.2 Company Snapshot
16.13.3 Product Overview
16.13.4 Business Overview
16.13.5 SWOT Analysis
16.13.6 Recent Developments
16.14 New England Biolabs
16.14.1 Company Overview
16.14.2 Company Snapshot
16.14.3 Product Overview
16.14.4 Business Overview
16.14.5 SWOT Analysis
16.14.6 Recent Developments
16.15 PacBio
16.15.1 Company Overview
16.15.2 Company Snapshot
16.15.3 Product Overview
16.15.4 Business Overview
16.15.5 SWOT Analysis
16.15.6 Recent Developments
16.16 PerkinElmer
16.16.1 Company Overview
16.16.2 Company Snapshot
16.16.3 Product Overview
16.16.4 Business Overview
16.16.5 SWOT Analysis
16.16.6 Recent Developments
16.17 Promega Corp.
16.17.1 Company Overview
16.17.2 Company Snapshot
16.17.3 Product Overview
16.17.4 Business Overview
16.17.5 SWOT Analysis
16.17.6 Recent Developments
16.18 Qiagen
16.18.1 Company Overview
16.18.2 Company Snapshot
16.18.3 Product Overview
16.18.4 Business Overview
16.18.5 SWOT Analysis
16.18.6 Recent Developments
16.19 Thermo Fisher Scientific
16.19.1 Company Overview
16.19.2 Company Snapshot
16.19.3 Product Overview
16.19.4 Business Overview
16.19.5 SWOT Analysis
16.19.6 Recent Developments
16.20 Zymo Research Corp.
16.20.1 Company Overview
16.20.2 Company Snapshot
16.20.3 Product Overview
16.20.4 Business Overview
16.20.5 SWOT Analysis
16.20.6 Recent Developments
17 Appendix
17.1 Self-Assessment Form

Companies Mentioned

  • Abcam, PLC
  • Active Motif, Inc.
  • Bio-Rad Laboratories
  • Creative Biogene
  • Diagenode
  • EpiCypher
  • EpiGentek Group, Inc.
  • Everon Life Sciences
  • F Hoffmann-La Roche, Ltd.
  • Fios Genomics
  • GenomeScan
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs
  • PacBio
  • PerkinElmer
  • Promega Corp.
  • Qiagen
  • Thermo Fisher Scientific
  • Zymo Research Corp.